Boston Scientific Corporation

NYSE:BSX Stock Report

Market Cap: US$111.1b

Boston Scientific Future Growth

Future criteria checks 3/6

Boston Scientific is forecast to grow earnings and revenue by 18.1% and 9% per annum respectively. EPS is expected to grow by 17.9% per annum. Return on equity is forecast to be 16.8% in 3 years.

Key information

18.1%

Earnings growth rate

17.9%

EPS growth rate

Medical Equipment earnings growth16.8%
Revenue growth rate9.0%
Future return on equity16.8%
Analyst coverage

Good

Last updated16 Jul 2024

Recent future growth updates

Recent updates

Boston Scientific Q2 Earnings Preview: Can The Rally Continue?

Jul 17

Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching

Jul 05
Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching

Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?

Jun 21
Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?

Boston Scientific Has Become A Standout Growth Story In Med-Tech

Jun 13

Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price

Jun 08
Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price

Is Boston Scientific (NYSE:BSX) Using Too Much Debt?

May 10
Is Boston Scientific (NYSE:BSX) Using Too Much Debt?

Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return

Apr 22
Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return

Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash

Apr 05

A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

Mar 26
A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease

Feb 29
We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease

What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E

Feb 15
What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E

Is Boston Scientific (NYSE:BSX) A Risky Investment?

Feb 02
Is Boston Scientific (NYSE:BSX) A Risky Investment?

Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital

Jan 19
Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital

Boston Scientific: Portfolio Updates Driving Top-Line Growth

Jan 17

Boston Scientific: Continued M&A Drives More Growth

Jan 10

Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?

Dec 04
Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?

Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?

Nov 03
Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?

Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue

Oct 30

ADVENT Offers Up An Early Present For Boston Scientific Investors

Aug 28

Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

Aug 24
Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly

Jul 25
Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly

Boston Scientific Remains Operationally Sound But May Have Limited Upside

Jul 14

Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital

Jul 10
Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital

Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate

May 21
Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate

Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly

Apr 18
Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly

Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture

Apr 03
Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture

Boston Scientific Stands Out With Strong, Diversified Growth Profile

Feb 15

Boston Scientific Non-GAAP EPS of $0.45 misses by $0.02, revenue of $3.24B in-line

Feb 01

Boston Scientific sees double digit EPS growth in 2023 - JPMorgan Healthcare conference

Jan 11

Earnings and Revenue Growth Forecasts

NYSE:BSX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202619,3283,2613,9344,36124
12/31/202517,6072,7352,9373,77130
12/31/202416,0032,2012,3073,08231
3/31/202414,7071,7651,7262,477N/A
12/31/202314,2401,5701,8222,503N/A
9/30/202313,7571,1911,7362,353N/A
6/30/202313,4008611,5592,125N/A
3/31/202313,0458461,2561,774N/A
12/31/202212,6826421,0081,526N/A
9/30/202212,5675966291,197N/A
6/30/202212,3298286681,192N/A
3/31/202212,1627541,0071,528N/A
12/31/202111,8889851,3981,870N/A
9/30/202111,4701,1011,7012,065N/A
6/30/202111,1965261,9392,243N/A
3/31/202110,1222011,6041,869N/A
12/31/20209,913-1151,2191,508N/A
9/30/202010,1083,6851,2421,527N/A
6/30/202010,1573,9801,0081,386N/A
3/31/202010,7854,2879861,409N/A
12/31/201910,7354,7001,4271,836N/A
9/30/201910,3921,0907821,163N/A
6/30/201910,0771,3968261,162N/A
3/31/20199,9371,797148467N/A
12/31/20189,8231,671-6310N/A
9/30/20189,670670686975N/A
6/30/20189,500521653926N/A
3/31/20189,2671121,3591,626N/A
12/31/20179,048104N/A1,426N/A
9/30/20178,831843N/A1,418N/A
6/30/20178,714788N/A935N/A
3/31/20178,582435N/A1,059N/A
12/31/20168,386347N/A1,182N/A
9/30/20168,09581N/A835N/A
6/30/20167,878-345N/A1,274N/A
3/31/20167,595-36N/A913N/A
12/31/20157,477-239N/A691N/A
9/30/20157,314-396N/A711N/A
6/30/20157,272-155N/A649N/A
3/31/20157,302-253N/A874N/A
12/31/20147,308-119N/A1,269N/A
9/30/20147,258288N/A1,104N/A
6/30/20147,147240N/A1,009N/A
3/31/20147,083366N/A1,121N/A
12/31/20137,070-121N/A1,110N/A
9/30/20137,126-168N/A1,204N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BSX's forecast earnings growth (18.1% per year) is above the savings rate (2.4%).

Earnings vs Market: BSX's earnings (18.1% per year) are forecast to grow faster than the US market (14.7% per year).

High Growth Earnings: BSX's earnings are forecast to grow, but not significantly.

Revenue vs Market: BSX's revenue (9% per year) is forecast to grow faster than the US market (8.6% per year).

High Growth Revenue: BSX's revenue (9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BSX's Return on Equity is forecast to be low in 3 years time (16.8%).


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.